GlassScriptPhysician profile
Rigoberto Garza
NPI 1144679556
$14,502.68
in general payments reported to CMS, 2019-2025
30 companies · $3,997 in 2025
The $3,997 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $24.08 · 2021: $150 · 2022: $1,909 · 2023: $4,014 · 2024: $3,724 · 2025: $3,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,529.67 |
| Education | $205.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,736.63 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,812.69 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Amgen INC. | $1,421.44 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,273.59 | 2022-2025 | Dupixent |
| Genzyme Corporation | $1,052.28 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $863.44 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Sanofi-Aventis U.S. LLC | $670.33 | 2022-2025 | |
| Csl Behring | $480.11 | 2022-2025 | Andembry, Hizentra, Haegarda |
| Optinose US, INC. | $459.02 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $438.98 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $386.33 | 2022-2025 | Orladeyo |
| Genentech USA, INC. | $317.50 | 2019-2025 | Xolair |
| Pfizer INC. | $267.31 | 2019-2025 | |
| Abbvie INC. | $217.55 | 2022-2025 | |
| Octapharma USA, INC. | $212.81 | 2022-2025 | Cutaquig, Panzyga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $177.09 | 2024-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $173.08 | 2025 | Neffy |
| Grifols USA, LLC | $111.27 | 2024-2025 | Xembify |
| Heron Therapeutics, INC. | $107.22 | 2021 | |
| Galderma Laboratories, L.P. | $67.16 | 2025 | Nemluvio |
| Alk-Abello, INC | $44.24 | 2025 | Ragwitek, Odactra, Grastek |
| Mylan Specialty L.P. | $43.81 | 2022-2023 | Yupelri |
| Blueprint Medicines Corporation | $27.24 | 2023 | Ayvakit |
| Organon LLC | $24.18 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.96 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Paratek Pharmaceuticals, INC. | $22.12 | 2025 | Xhance |
| Shire North American Group INC | $21.88 | 2019 | |
| Sanofi Pasteur INC. | $21.25 | 2024 | |
| Leo Pharma INC. | $15.26 | 2022 | |
| Phadia US INC. | $12.91 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rigoberto Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.